A genitourinary oncologist provides insights on the treatment decision-making process and the roles of guidelines for prostate cancer. Alicia Morgans, MD, MPH: Treatment decisions for localized ...

Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions The tumor immune microenvironment of prostate ...

Researchers have uncovered a rare inherited mutation linked to prostate cancer—and it could help identify at-risk families ...

A scientist whose discoveries about prostate cancer have led to lifesaving treatments is now shedding light on an emerging and deadlier form of the disease: neuroendocrine prostate cancer (NEPC). Most ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme ...

Mutations in a genetic region that regulates RNA stability could influence prostate cancer outcomes and drug resistance, according to new work from scientists at Fred Hutchinson Cancer Center ...

Scientists have learned that prostate cancers can vary significantly among patients and that there are often differences within each patient's tumor. However, the study published Aug. 28 in Nature ...

Prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient’s metastatic prostate cancer. However, in 15–20% of patients with castration-resistant prostate ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

Leveraging Circulating Tumor DNA to Optimize the Initial Management of Childhood Renal Tumors The article by Hussain et al entitled “Evolving Role of Prostate-Specific Membrane Antigen-Positron ...